/
© 2026 RiffOn. All rights reserved.
  1. BiotechTV - News
  2. Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today
Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

BiotechTV - News · Dec 11, 2025

Medra raised $52M to build "physical AI scientists," combining AI reasoning with adaptive robotics to automate and scale scientific discovery.

AI's Real Bottleneck in Biotech is Physical Experimentation, Not Hypothesis Generation

The founder of AI and robotics firm Medra argues that scientific progress is not limited by a lack of ideas or AI-generated hypotheses. Instead, the critical constraint is the physical capacity to test these ideas and generate high-quality data to train better AI models.

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today thumbnail

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

BiotechTV - News·2 months ago

Medra's AI Platform Offers 'Tunable Autonomy,' Letting Scientists Choose Their Level of Control

Recognizing that scientists require varying levels of control, the system's autonomy can be dialed up or down. It can function as a simple experiment executor, a collaborative partner for brainstorming, or a fully autonomous discovery engine. This flexibility is designed to support, not replace, the human scientist.

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today thumbnail

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

BiotechTV - News·2 months ago

Physical AI Platforms May Democratize Biotech, Letting Solo PhDs Launch Ventures Without Labs

The combination of AI reasoning and robotic labs could create a new model for biotech entrepreneurship. It enables individual scientists with strong ideas to test hypotheses and generate data without raising millions for a physical lab and staff, much like cloud computing lowered the barrier for software startups.

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today thumbnail

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

BiotechTV - News·2 months ago

Next-Gen Lab Automation Is 'Physical AI,' Not Industrial Robotics, Mimicking Self-Driving Cars

Unlike pre-programmed industrial robots, "Physical AI" systems sense their environment, make intelligent choices, and receive live feedback. This paradigm shift, similar to Waymo's self-driving cars versus simple cruise control, allows for autonomous and adaptive scientific experimentation rather than just repetitive tasks.

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today thumbnail

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

BiotechTV - News·2 months ago